Novo Nordisk is to invest more than $4bn in US manufacturing as it battles to keep up with booming demand for its obesity and diabetes drugs Wegovy and Ozempic
9
votes
-
-
Novo Nordisk suggested to senior UK government officials that they could “profile” benefit claimants – those who are most likely to return to the labour market
17 votes -
Wegovy may be valuable new option for heart failure patients
6 votes -
Most patients using weight-loss drugs like Wegovy stop within a year, data show
10 votes -
US medical insurers clamping down on doctors who prescribe Ozempic for weight loss
22 votes